docetaxel + cisplatin + afatinib

This is a **combination regimen** comprised of three agents: docetaxel, cisplatin, and afatinib. - **Docetaxel** is a small molecule chemotherapeutic agent that acts as a microtubule inhibitor, preventing microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells[4]. - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, ultimately causing DNA damage and triggering cell death. - **Afatinib** is a small molecule, irreversible inhibitor of the ErbB family of tyrosine kinases, most notably the epidermal growth factor receptor (EGFR), blocking downstream signaling essential for tumor growth and survival[2]. The combination of these agents is under clinical investigation for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), with the rationale that dual cytotoxic chemotherapy (docetaxel and cisplatin) combined with EGFR inhibition (afatinib) may have synergistic antitumor activity[1][3][6].